Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale ≥ 3)~Exclusion Criteria:~* Active ocular disease, corneal abnormalities other than pterygium, active ocular infection, or any ocular pathology unrelated to pterygium in either eye that could affect the assessment of the pterygium~* History of ocular herpes disease in either eye~* Any ocular surgical procedure within the last 3 months~* Female patients who are pregnant, nursing, or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT-001 Ophthalmic Solution Single dose (Type: EXPERIMENTAL): One drop in the study administered one time only for one day
- Vehicle (Type: PLACEBO_COMPARATOR): One drop in the study administered three times daily (TID) for 4 weeks
- CBT-001 Ophthalmic Solution Multidose (Type: EXPERIMENTAL): One drop in the study administered three times daily (TID) for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).